No significant associations were observed between PD-L1 or LC3B expression and patient age, sex, tumour characteristics (location, lateralization, or size), presence or absence of adjuvant chemotherapy or number of adjuvant chemotherapy cycles, second-line chemotherapy, second-line surgery, or second-line radiotherapy (P > 0.05), as summarized in Table 2. The gene discussed is MAP1LC3B; the disease is neoplasm.